Global infectious disease test device market is valued approximately at USD 16.4 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 5.60% over the forecast period 2020-2027. Diagnosis of infectious disease involves identifying the presence of a foreign antigen / organism using diagnostic tools like kits. Most of the currently available standard diagnostic test kits are for bacterial infections and sexually transmitted diseases.Malaria, Dengue, Leptospirosis and others diagnostic tests should, however, be replaced by molecular techniques in the future. In spite of significant improvements in sanitation practices and medicine, the global prevalence of infectious diseases such as influenza, HPV, hepatitis, HIV and tuberculosis is considerably high, which drives the market. According to NCBI, “Worldwide, 17 million HIV-infected people are receiving these life-extending drugs?an impressive number given that only 2.2 million people were on ART in 2005.” Medicare has revised its mechanism for reimbursement of some IVD tests, including molecular infectious disease tests. Some of these molecular pathology tests do not have their own HCPCS (Healthcare Common Procedure Coding System) codes, but are charged using unlisted codes, which is the restraining factor. Reimbursement for In Vitro Diagnostic (IVD) Tests examines the U.S. reimbursement system for IVD testing, which focuses on key issues of industry concern. It covers only commercialized tests, excluding those used primarily for research or developmental purposes One of the key factors leading to increased use of molecular diagnostics and genomics & proteomics technologies in infectious disease testing is growing patient awareness of the benefits of personalized medicine. Genome Canada, a funding source for genomics and proteomics, has announced plans to invest $16 million between the April 2015 to March 2017 period.

The regional analysis of global infectious disease test device market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World North America accounted for a share of just over 44.0 percent of the global market in 2019, and it is expected that this trend will continue through the forecast period. This is due to high levels of awareness among practitioners and patients, proactive government initiatives and the presence of sophisticated health care infrastructure. Asia Pacific is expected to register the highest CAGR, driven by favorable government initiatives for infectious disease testing, high unmet medical needs, economic development and consequent rise in disposable income, and increased healthcare spending in emerging countries such as China, India , and South Korea.

Major market player included in this report are:

Abbott Laboratories
Becton, Dickinson and Company
Biom?rieux SA
Bio-Rad Laboratories
Danaher Corporation
Diasorin
Luminex
Meridian Bioscience
Quidel
Roche Diagnostics
Siemens AG
Thermo Fisher Scientific

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
by Product & Service
Assays, Kits, & Reagents
Instruments
Services and Software
by Disease Type
Hepatitis
HIV
CT/NG
HAIs
HPV
TB
Influenza
Other Diseases
by Technology
Immunodiagnostics
Clinical Microbiology
PCR
INAAT
DNA Sequencing & NGS
DNA Microarrays
Other Technologies
by End User
Hospitals/Clinical Laboratories
Reference Laboratories
Physician Offices
Academic/Research Institutes
Other End Users
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027

Target Audience of the Global Urgent Care Center Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors